Physician profile
Joel Freitag
NPI 1003928235
$12,677.49
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,771 · 2020: $3,208 · 2021: $3,298 · 2022: $3,400.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,314.42 | 2019-2022 | |
| Biogen, INC. | $1,015.13 | 2019-2022 | |
| Emd Serono, INC. | $963.75 | 2019-2022 | |
| Abbvie INC. | $862.07 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $825.72 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $795.50 | 2019-2022 | |
| Allergan, INC. | $695.49 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $652.81 | 2019-2022 | |
| Genzyme Corporation | $452.32 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $445.96 | 2019-2022 | |
| Ucb, INC. | $424.30 | 2019-2022 | |
| Amgen INC. | $407.88 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $262.27 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $237.12 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $233.85 | 2019-2021 |
Show all 50 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Freitag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.